Altria’s shares surged to a fresh 52-week high on Tuesday, climbing past $76 after closing at $72.89 the day before. The stock has gained over 30% this year, fueled by a better-than-expected Q1 with earnings per share of $1.32 beating forecasts of $1.25. Revenues rose 5.3% year over year to $4.76 billion, topping estimates by $180 million.
The company provided optimistic guidance for 2026, projecting EPS between $5.56 and $5.72, closely aligning with analyst expectations. Investors were also drawn by a quarterly dividend of $1.06 per share, which translates into a yield of about 5.5%. Altria's commitment to returning income stands out, with a streak of 56 consecutive years of dividend payments.
Mixed Analyst Views and Insider Moves
Despite the rally, Wall Street remains split. The consensus rating is 'Hold' with an average price target of $70.78, which lags behind current trading levels. UBS and Bank of America are more bullish, with targets around $79, bolstered by recent regulatory developments favoring domestic tobacco firms like Altria. Conversely, Jefferies downgraded to 'Underperform' citing a $60 price target.
Inside the company, two directors sold shares in May, reducing their stakes by about 7%. Institutional investors continue to control over half the float, with some funds adding positions in the second quarter.
The FDA’s new proposal requiring foreign tobacco manufacturers to register facilities could strengthen Altria's domestic position, supporting growth in oral tobacco sales seen through May. This regulatory backdrop adds another layer to the stock’s upward momentum.
This is an informational piece and not an investment recommendation.
